The most common primary CNS tumors are gliomas, where other than a few subtypes such as oligodendrogliomas, the survival has remained unchanged despite advances in surgical, chemo-and radiation therapy, especially for the most malignant and common glioma; glioblastoma multiforme (GBM). Recent novel therapies like immunoand gene therapy have shown some promise in existing pre-clinical models, but have failed to demonstrate therapeutic benefit in patients. The reason(s) for such failures include our incomplete understanding of the molecular pathogenesis of these tumors and also due to testing of novel biological therapies in less than ideal pre-clinical models, which for the most part have included xenografts established in mice from glioma cell lines or patient explants. Transgenic mouse models offers an opportunity to develop and utilize an easily replenished, reproducible, manipulated spontaneous and more appropriate pre-clinical model of human cancers. Here we highlight on how mouse models are generated using several techniques and how mouse models have come to the forefront to address several issues such as identifying novel tumour modifier genes of central and peripheral nervous system tumours. Lastly we discuss how mouse models may provide an invaluable tool in pre clinical drug screening and testing.
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Brief Introduction
The most common primary CNS tumors are gliomas, where other than a few subtypes such as oligodendrogliomas, the survival has remained unchanged despite advances in surgical, chemo-and radiation therapy, especially for the most malignant and common glioma; glioblastoma multiforme 
Pro-nuclear injection
Micro-injection has been used extensively to introduce foreign DNA into the male pronuclei of fertilized mammalian eggs, which are then implanted into a foster mother for the remainder of embryonic development, In the presence of the recombinase, which is both necessary and sufficient for catalyzing recombination between the recognition sites, the intervening DNA segment is deleted.
The Cre-loxP recombinase system is at present the most widely system used in mammals.
Using specific cell/tissue-type promoters, and Table 1 ). Majority of the current strategies for creating transgenic mouse models is based on manipulating the mouse genome, using some of the techniques discussed above, to over express and/or loose expression of these relevant molecular alterations that have been deciphered from human tumor data (Table 2 ).
animal Models of Cns Tumours
For example, there are transgenic mouse glioma models that target the Rb or p53 cell cycle regulatory pathways. Astrocyte-specific Figure 5 . RCAS-tva system. The tva receptor is specific for recognizing and incorporating the RCAS retrovirus.
Cell or tissue specific transgenic tva mice (such as GFAP-tva) are made and can be mated with other genetically modified mice (such as Ink4A/Arf null mice). The RCAS retrovirus, with the transgene of interest, can be inoculated into the adult tva mice, either alone or in combination, to yield focal gliomas, as undertaken by Holland et al. Of interest, expression of activated p21-Ras in adult astrocytes leads to senescence, so with EGFRvIII, have also been obtained by our ES transgenesis model [7] and those with the RCAS-tva system [13] . In both, expression of EGFRvIII by itself is not transforming, as it is a progression not an initiation factor. In the RCAS-tva system, retroviral transduction of both EGFRvIII and CDK4 in mice null for p53, was required for formation of mixed gliomas. 11 and p53 could be deleted was generated [17] . These mice developed MPNST, which is in keeping with the loss of p53 in a large subset of human MPNST, and suggests that a second hit with p53 loss is involved in this malignant conversion of neurofibromas.
Neurofibromatosis 2
Similar to NF-1, the cloning of the Nf-2 gene on chromosome 22q soon led to it being knocked out in mice. The Nf-2 (-/-) null mice died in embryo similar to Nf-1 null mice, with the heterozygotes developing osteosarcomas and other tumors, but not the expectant schwannomas [29, 30] . The Cre-loxP system was used to overcome this embryonic lethality when Nf-2 was deleted globally, with schwann cell specific Cre recombinase expression leading to development of schwannomas [31] . Meningiomas, which are highly prevalent in NF-2 patients also formed, with meninges specific excision of the Nf-2 gene using adenoviral delivered Cre into the CSF of NF-2/ flox mice [32] .
Potential use of transgenic mouse models
The ability to manipulate the mouse genome Although much progress has been made in development of better human disease models using transgenic and other technologies, one must remember that significant epigenetic differences between mice and humans do exists, and the ultimate test of therapies will still rely on properly designed clinical trials.
However, with better models of human diseases such as those being developed for nervous system tumors using transgenic technologies, the chance of promising pre-clinical therapies translating to efficacy in clinical trials should be much improved in the future.
